Efficacy of tolterodine in children with overactivebladder

To investigate the effect of treatment on the bladder, ultrasonographic data at baseline and the third month were compared with the oxybutynin group.Results: The dysfunctional voiding symptom scores significantly decreased after the third month of tolterodine treatment (p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: Tolterodine is an anticholinergic drug used for the treatment of overactive bladder.

📊

Key Findings & Data:We evaluated the effects of tolterodine on clinical symptoms and compared its efficacy with that of oxybutynin in terms of bladder capacity, bladder wall thickness, and post-void residual volume in children with overactive bladder.Material and Methods: Twenty-six patients who were treated with tolterodine for overactive bladder (20 girls, mean age 8.0±2.2 years) were evaluated retrospectively.

💡

Conclusion & Impact:To investigate the effect of treatment on the bladder, ultrasonographic data at baseline and the third month were compared with the oxybutynin group.Results: The dysfunctional voiding symptom scores significantly decreased after the third month of tolterodine treatment (p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: Tolterodine is an anticholinergic drug used for the treatment of overactive bladder. We evaluated the effects of tolterodine on clinical symptoms and compared its efficacy with that of oxybutynin in terms of bladder capacity, bladder wall thickness, and post-void residual volume in children with overactive bladder.Material and Methods: Twenty-six patients who were treated with tolterodine for overactive bladder (20 girls, mean age 8.0±2.2 years) were evaluated retrospectively. Twenty patients with overactive bladder who had undergone oxybutynin treatment (15 girls, mean age 7.6±1.8 years) served as the control group. Dysfunctional voiding symptom scoring was used to evaluate the clinical response to tolterodine. To investigate the effect of treatment on the bladder, ultrasonographic data at baseline and the third month were compared with the oxybutynin group.Results: The dysfunctional voiding symptom scores significantly decreased after the third month of tolterodine treatment (p

Özet

Amaç: Tolterodine, aşırı aktif mesanenin tedavisinde kullanılan antikolinerjik bir ilaçtır. Bu çalışmada, aşırı aktif mesane tanısı almış çocuklardatolterodinin klinik bulguları üzerindeki etkileri ile mesane kapasitesi,mesane duvar kalınlığı ve post-miksiyonel rezidü üzerindeki etkileri oksibutininin ile karşılaştırıldı. Gereç ve Yöntemler: Aşırı aktif mesane tanısı alıp tolterodin ile tedaviedilen 26 hasta (ortalama yaş 8,0±2,2 yıl) geriye dönük olarak değerlendirildi. Oksibutinin tedavisi alan aşırı aktif mesaneli 20 hasta (15 kız,ortalama 7,6±1,8 yıl) kontrol grubu olarak alındı. Klinik yanıtı değerlendirmek için disfonksiyonel işeme semptom skorlaması kullanıldı.Tedavi sonrası mesanedeki değişikliklerin değerlendirilmesi amacı ilebaşlangıçtaki ve üçüncü aydaki ultrasonografik veriler oxybutinin grubuile karşılaştırıldı. Bulgular: Tolterodin tedavisinin üçüncü ayında, disfonksiyonel işeme semptom skorları anlamlı olarak azaldı (p

🔖

Cite This Article

CANPOLAT, N., KOÇ, B., ADALETLİ, İ., SEVER, L., EMİR, H., ÇALIŞKAN, S. (2022). Efficacy of tolterodine in children with overactivebladder. Türk Pediatri Arşivi, Cilt: 55 - Sayı: 3, 284–289. https://ajindex.com/articles/640969

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn 2016; 35: 471–81.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543–62. Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010; 29: 112–5.
Schröder A, Thüroff JW. New strategies for medical management of overactive bladder in children. Curr Opin Urol 2010; 20: 313–7.
Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Indian J Physiol Pharmacol 2013; 57: 343–53.
Farhat W, Bägli DJ, Capolicchio G, et al. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 2000; 164: 1011–5. Nevéus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 2006; 176: 314–24.
Ayan S, Topsakal K, Gokce G, Gultekin EY. Efficacy of combined anticholinergic treatment and behavioral modification as a first-line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. The J Urology 2007; 177: 2325–9.
Ayan S, Kaya K, Topsakal K, Kilicarslan H, Gokce G, Gultekin Y. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. BJU Int 2005; 96: 411–4. Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr 2006; 43: 980–3.
Goessl C, Sauter T, Michael T, Bergé B, Staehler M, Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 2000; 55: 414–8.
Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoorne J, Vande Walle J. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. Eur Urol 2004; 45: 240–4.
Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Comparison of the effectiveness and side-effects of tolterodine and oxybutyni